Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.com 

Biotech stocks are breaking out of a five-year range because the threat from oil and interest rates was priced in years ago. Many of the most undervalued growth stocks are now in biotech, and research discovery is getting a boost from AI, making it perhaps the sector with most to gain from AI productivity. Charts support it: daily volume spikes have tended to mark major bottoms, the weekly held its quarterly averages to form a base, and the monthly shows a healthy pullback to the one-year EMA. … Show more

Fintech is investing while biotech is gambling: roughly 90% of biotechs fail versus 10% of fintechs. Most fintechs are growing 25-30% or more yet trade at record-low valuations, while biotech is already up 90% and in a bubble driven by buyout mania. x.com 

Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

Biotech looks like a sector that wants to trend higher. Biotech M&A drove a heavy-volume weekly move to the top of a multi-month range; it just needs some help from the macro environment. x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

Money keeps rotating into healthcare, which is where market strength is. The rotation into biotech continues, with leveraged biotech exposure offering the fireworks. Pharma offers steadier, broad exposure with no dominant holding and a chart that is fine enough. x.com  x.com 

ARKG's genomics thesis faces a timing problem, as much of the index consists of companies with no important clinical data readouts until 2028 or later. Clinical trials remain painstakingly long, and AI is moving faster than trial progress can keep up with, raising the question of when the broader biotech theme becomes overextended. x.com 

Biotech is the next AI trade, as AI turns drug discovery from a 10-year guessing game into a data problem while investors still treat the sector like a casino. Tempus AI uses a large clinical dataset for AI diagnostics; Recursion maps over a trillion cells with Genentech and Sanofi as partners; CRISPR Therapeutics has catalysts before end-2026; Absci designs antibodies with generative AI and starts Phase 2; Schrödinger sells physics-plus-AI design software and posted a surprise profit. x.com  … Show more